老年非小细胞肺癌患者药物治疗研究进展  

Research Progression on the Drug Therapy for Elderly Patients with Non-small Cell Lung Cancer

作　　者：李杰[1] 上官丹罡 袁松泉 程泽能[1] 

机构地区：[1]中南大学湘雅药学院,湖南长沙410013 [2]湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院,湖南长沙410013 [3]株洲市外国语学校,湖南株洲412000

出　　处：《肿瘤药学》2017年第2期146-151,共6页Anti-Tumor Pharmacy

基　　金：国家自然科学基金面上项目(81573498)

摘　　要：肺癌是目前世界上发病率最高的恶性肿瘤之一,然而,老年患者在临床研究中的代表性不足,导致缺乏指导治疗决定的证据。目前,辅助性化疗通常被推荐用于IB^III期非小细胞肺癌(NSCLC)手术切除术后治疗,老年晚期NSCLC患者的治疗方案则主要为单药化疗以及以铂类为基础的联合化疗。此外,靶向治疗及免疫靶向治疗成为新的研究方向。本文主要对辅助化疗及老年晚期NSCLC患者的药物治疗相关临床研究证据进展进行综述。Lung cancer is one of the malignant tumors with high incidence. However, elderly patients are underrepresented in clinical studies, leading to a paucity of evidence to guide treatment decisions. At present, adjuvant chemotherapy is recommended for stage IB - III non-small cell lung cancer （NSCLC） after surgical resection. And the treatments for elderly patients with advanced NSCLC are mainly single-agent chemotherapy and platinum-based combination chemotherapy. Moreover, targeted therapy and immuno-targeted therapy have become new research directions. In this review, we summarized the progress of clinical research on adjuvant chemotherapy and medical treatment for elderly patients with advanced NSCLC.

关 键 词：非小细胞肺癌 老年患者 化疗 

分 类 号：R734.2[医药卫生—肿瘤]